On August 30, 2022, the FDA responded to MAPS’ request to lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2), citing an incomplete response to the hold. Read the FDA’s letter here.
On August 30, 2022, the FDA responded to MAPS’ request to lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2), citing an incomplete response to the hold. Read the FDA’s letter here.